Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Histologically or cytologically confirmed metastatic colorectal cancer (adenocarcinoma)
At least one measurable lesion (RECIST criteria)
Life expectancy ≥ 3 months
ECOG performance status 0-2
Adequate hematologic function: ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥ 100×109 /L
Adequate renal function: Cr ≤ 1.25×ULN or Creatinine clearance ≥ 60 ml/min
Adequate hepatic function: BIL ≤ 1.5×ULN, ALT/AST ≤ 2.5×ULN, Alkaline phosphatase ≤ 5×ULN
Patients have not previously received palliative chemotherapy, immunological/ biological treatment
No adjuvant chemotherapy in last six months
Target lesion has not received local radiotherapy
Written informed consent

Diagnosis of colorectal neuroendocrine tumor, undifferentiated carcinoma, adenosquamous carcinoma, squamous cell carcinoma
Evidence of serious or uncontrolled infection
Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
Pregnant or lactating women
Women of childbearing potential refused to practice acceptable methods of birth control to prevent pregnancy
Allergic to any of the study drug
Intestinal obstruction, intestinal perforation, or stroke within 3 months
Participation in other clinical studies

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer